Home Today's Paper Most Popular Video Gallery Photo Gallery
Subscription Blog Signin Register
Logo
Monday, May 28, 2018 07:23:43 AM
Follow Us On: Facebook Twitter Twitter Twitter Twitter

Innovation doesn't happen by accident

By
13th-May-2018       
Comments
Share your thought
Post a comment »
Read all () »

Mark J. Alles :
But today, some question the real impact of innovation in healthcare and if it is worth it. The European Commission is currently considering modifications to the intellectual property framework in Europe, partially in response to the chronic sustainability and affordability challenges among healthcare systems. But some of these proposals likely put the healthier future we all envision at risk by stifling innovation that is critical to economic growth and improving healthcare.
There is no doubt that we face challenges in healthcare, but solutions must address these challenges while still fostering growth and progress. Too often, this debate is reduced to a single issue: the perceived high cost of medicines. However, this is a massive oversimplification of a much bigger picture. The complexities of managing healthcare expenditures in Europe while driving health gains and economic prosperity over the long term are great. In this effort, incentives must encourage innovation, not deter it.  Understanding the facts is an important start:
First, medications account for less than 15% of overall EU healthcare spending, and several recent studies refute the long-held belief that medicine costs are rising uncontrollably. A recent study on the projected impact of medicines in the UK, France, Germany, Spain and Italy shows that the net pharmaceutical expenditure is projected to rise just 1-2% over the next five years, in line with projected economic growth. These modest increases should not be blamed for long-term sustainability issues across the entire healthcare system.
Second, we must consider the role of today's intellectual property framework, which aligns appropriate incentives to drive innovation with continuing value for generations through the availability of lower-cost generic medicines when novel medicines lose their exclusivity. Of course, we need to collaborate on solutions for short-term affordability issues, and the biopharmaceutical sector has shown its willingness and ability to advance positive solutions. But we must also preserve what is working: today's incentives framework stimulates transformative research, ensures competition, and rewards innovators for investing in the challenging research required to discover new medicines.
The incentives framework in the EU has proven itself, successfully driving innovation and reducing the financial impact of diseases across many therapeutic areas. For example, in rare diseases, the Orphan Regulation was introduced precisely to spur innovation in some of the most difficult-to-treat diseases affecting small numbers of people. As a result, people with life-threatening and seriously debilitating rare diseases in Europe have benefitted from significant investment and a dramatic increase in available medicines to treat their conditions - from just 8 medicines for orphan indications 15 years ago to more than 140 medicines today.
At Celgene, more than ten years of research focused on multiple myeloma, a rare, life-threatening, blood cancer, allowed us to develop three novel medicines that have helped contribute - along with other therapies - to the doubling of the five-year survival rate for patients living with multiple myeloma.
The first of Celgene's multiple myeloma medicines will lose market exclusivity later this year, joining the medicine cabinet of generics that will continue to deliver value for society at low costs for as long as they remain necessary for the treatment of a specific disease.
Beyond offering a tested and proven framework, incentives are also responsible for encouraging investment in high-risk research that has the potential to one day cure diseases like cancer, dementia and heart disease. At Celgene, we invest nearly 40% of our revenues on average back into R&D annually. This investment is risky. In fact, we recently stopped clinical studies on a compound for Crohn's Disease, because our investigational medicine did not show enough impact on the disease to support continued clinical development in this setting. We will never recover our investment on this compound, but we took this risk because patients need new and better options. This decision and others like it are possible because we currently work within an innovation framework that rewards those successful medicines that do make a difference for patients.
Finally, we are very aware of how innovation incentives impact industrial policy, including job creation and economic investment. For instance, Celgene, a U.S.-based company, chose to establish operations in Europe 11 years ago because of the confidence created by the EU incentives environment. Without such support, Celgene may not have established operations in Europe, that brought more than 2000 jobs, significant R&D investment, and, of course, innovative medicines to patients in Europe.
The EU's decisions about the future of incentives for biopharmaceutical innovation will have broad implications. Global competition to attract investments is increasing.  Maintaining a competitive environment is critical to continue attracting investment as well as stimulating the creation of new ones. And while medical technologies have advanced over the past 30 years, reimbursement models have not. Appropriate reimbursement models can also align the right incentives and allow us to seize the opportunities that science is delivering.
All that to say, innovation doesn't happen by accident; it is the result of high-risk, long-term investment which is only possible when companies and investors are confident that they will be able to make reasonable returns if successful. The limited period of exclusivity within today's incentives framework is key to this virtuous cycle of investment. With the right incentives in place, biopharmaceutical companies can continue to invest in R&D and enable broader access to innovative medicines that can have a life-changing impact on patients and the healthier world we are creating together.

(Mark J. Alles is Chairman and CEO of Celgene).

Tariff
Add Rate

News Archive

Inside The New Nation

Editorial »

Teesta treaty still a far cry


YESTERDAY, Bangladesh Prime Minister Shiekh Hasina and West Bengal Chief Minister Mamata Banerjee held a closed-door meeting for about an hour at a five-star hotel in Kolkata. Although they discussed a lot of issues such as education, trade and economic ties, the much anticipated Teesta water-sharing deal did not figure ...

Entertainment »

Kajol unveils her wax statue at Madame Tussauds Singapore


Bollywood fans, prepare yourself! Kajol joined the IIFA Awards party at Madame Tussauds Singapore. Her figure is the newest addition to the International Indian Film Academy (IIFA) Awards Experience, an interactive zone where you can surround yourself with A-list Bollywood stars and experience stardom. The Bollywood legend herself came to ...

Entertainment »

Leading actors joining the voice over industry gives me hope: Pallavi Bharti


The existence of voice over artists was established only after popular names like Ranveer Singh, Bhuvan Bam and Sharad Kelkar dubbed for the leading characters of blockbuster movies. Pallavi Bharti - who herself is an immensely experienced and talented artist in the field - feels that the involvement of popular ...

International »

Florida, Alabama, Mississippi declare emergency ahead of storm


Reuters, Washington :Florida, Alabama and Mississippi declared states of emergency on Saturday as Subtropical Storm Alberto drove north toward the U.S. Gulf Coast, threatening to bring heavy rainfall and flooding to the coastal states by Monday.The first named Atlantic storm of 2018 is expected to intensify and bring wind speeds ...

Football »

Platini says FIFA must now end his ban, but probe goes on


Former UEFA president Michel Platini said Saturday he hoped FIFA would lift his ban over a controversial 1.8-million-euro payment after Swiss prosecutors said they had found no evidence so far to incriminate him."I hope that FIFA will have the courage and the decency to lift my suspension," Platini told AFP ...

Football »

Colombia`s national soccer team coach Jose Pekerman greets a boy next to James Rodriguez (right) and Radamel Falco Garcia, second from right, prior to an exhibition match at the Nemesio Camacho stadium in Bogota, Colombia on Friday. Colombia will warm up and play a friendly match against Egypt in Italy before heading to Russia for the 2018 FIFA World Cup.


Editorial »

Anti-Terrorism special tribunals not working for quick disposal


NEWS media reported that the two Anti-terrorism Special Tribunals formed last month for quick trial of militancy and terrorism cases are now working at a snail's pace. A small number of cases have been transferred to the tribunals while shortages of courtrooms and manpower are acute. After forming the tribunals ...

Entertainment »

Apu Biswas making comeback


Entertainment Desk :The actress, who kept herself away from the silver screen for family reasons, will be seen in Debashish Biswas's upcoming directorial venture Shashurbari Zindabad-2. The film's shooting will begin this week, informed Apu. 'I am looking forward to make my comeback through Debashish Biswas' upcoming film Shashurbari Zindabad-2, ...

Entertainment »

Deepika, Ranveer are likely to marry on Nov 19


After Sonam Kapoor and Anand Ahuja's big fat Punjabi wedding, looks like another popular couple is ready to tie the knot soon.Ever since the beginning of 2018, rumors of Ranveer Singh and Deepika Padukone tying the knot have been sending fans into a tizzy. We've been hearing news of guests ...

City »

BNP Standing Committee Member Dr Khondkar Mosharraf Hossain, among others, at a protest rally organised by Bangladesh Jatiya Dal at the Jatiya Press Club on Saturday demanding release of BNP Chairperson Begum Khaleda Zia and other leaders of the party.


International »

S Korea relieved about Trump-Kim summit revival efforts


AP, Seoul :South Korea on Saturday expressed cautious relief about the revived talks for a summit between President Donald Trump and North Korean leader Kim Jong Un following a whirlwind 24 hours that saw Trump canceling the highly-anticipated meeting before saying it's potentially back on.The statement by Seoul's presidential office ...

Editorial »

Narcotics sale continues despite countrywide crackdown


NARCOTICS trade continues unabated at some of the hotspots in the capital with drug dealers continually changing their tactics in the face of the ongoing nationwide anti-drugs crackdown. The people involved in the illicit trade have become vigilant, but sales haven't stopped. It is, however, difficult to comment about the ...

Back Page »

Fear Allah


Abdul Muqit Chowdhury :The Holy Quran reveals : This is the Book ; /in it is guidance sure, without doubt, /to those who fear God;/who believe in the Unseen/Are steadfast in prayer, /and spend out of what We/Have provided for them;/And who believe in the Revelation/Sent to thee,/And sent before ...

Cricket »

Pakistan bowl England out for 184, reach 50-1 in reply


AP, London :Pakistan provoked England's latest batting collapse by combining disciplined bowling with superb catching before showing resistance in its reply to dominate the opening day of the first test at Lord's on Thursday.A new international season started with some familiar problems for England, which stumbled to 43-3 after winning ...

City »

Textile Garments Workers Federation formed a human chain in front of the Jatiya Press Club on Friday to meet its various demands including reopening of Mastext Mills in Turag.


.

 
Items that you save may be read at any time on your computer, iPad, iPhone or Android devices.
 
Are you new to our website? Do you have already an account at our website?
Create An Account Log in here
Email this news to a friend or like someone
Email:
Write a comment to this news